Valuation: Sansure Biotech Inc.

Capitalization 10.38B 1.53B 1.3B 1.2B 1.13B 2.1B 146B 2.12B 14.24B 5.55B 69.39B 5.74B 5.61B 241B P/E ratio 2026 *
37.2x
P/E ratio 2027 * 27.2x
Enterprise value 10.38B 1.53B 1.3B 1.2B 1.13B 2.1B 146B 2.12B 14.24B 5.55B 69.39B 5.74B 5.61B 241B EV / Sales 2026 *
5.63x
EV / Sales 2027 * 4.32x
Free-Float
49.87%
Yield 2026 *
2.85%
Yield 2027 * 2.41%
04-29 Sansure Biotech Inc 2025 net profit down 27.8% y/y RE
04-29 Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-13 Sansure Biotech to Purchase Stake in Medical Research Company in Exchange for 4.02% Stake MT
03-12 Phil Rivers Technology Co., Ltd. announced that it expects to receive CNY 165 million in funding from Sansure Biotech Inc., Hunan Xiangjiang Sansure Biotech Industry Fund Partnership Enterprise (Limited Partnership) CI
03-11 Sansure Biotech Inc., Hunan Jinfurong Sansure Biotech Equity Investment Fund Partnership (Limited Partnership) and others agreed to acquire 2.17% stake in Phil Rivers Technology Co., Ltd. from Hainan Xunfeng Investment Consulting Center (Limited Partnership) for CNY 15 million. CI
02-27 Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-27 Sansure Biotech's Subsidiary Gets Nod to Trial Growth Hormone Injection As ISS Treatment MT
12-17 Sansure Biotech Gets China Nod for Four Testing Kits MT
11-03 Sansure Biotech Gets Registration Certificates for Pathogen Detection Kits MT
30/10/25 Sansure Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
22/10/25 Sansure Biotech to Set Up Medical Tech Partnership Fund MT
23/09/25 Sansure Biotech Gets China Approval for Staphylococcus Aureus Detection Kit MT
11/09/25 Sansure Biotech Inc. acquired an additional 10% stake in Hunan Sanway SepSMART Ltd from Sepset Biosciences Inc. for CNY 5 million. CI
1 day-4.25%
1 week+6.41%
Current month+6.41%
1 month-0.33%
3 months-6.60%
6 months-16.82%
Current year-3.49%
1 week 17.17
Extreme 17.17
19.1
1 month 17.07
Extreme 17.07
19.1
Current year 17.07
Extreme 17.07
22.8
1 year 17.07
Extreme 17.07
23.45
3 years 14.72
Extreme 14.72
26.36
5 years 14.72
Extreme 14.72
70.16
10 years 14.72
Extreme 14.72
105.1
Manager TitleAgeSince
Chief Executive Officer 58 07/07/2019
Director of Finance/CFO 50 07/07/2019
Corporate Officer/Principal 41 04/08/2025
Director TitleAgeSince
Chairman 58 22/04/2008
Director/Board Member 50 21/02/2020
Director/Board Member 62 17/07/2022
Change 5d. change 1-year change 3-years change Capi.($)
-4.25%+6.41%-9.25%+0.72% 1.54B
-3.15%+11.64%+139.89%+278.99% 13.25B
+0.27%+4.15%-37.23%-24.61% 10.21B
+0.89%+12.13%+21.01%-3.43% 6.27B
+0.41%+2.72%-6.86%-6.70% 5.73B
-7.61%-11.56% - - 4.74B
+2.02%+1.50%+93.26%+86.97% 4.6B
+3.02%+11.87%-27.22%-33.06% 4.24B
-0.89%+3.55%-11.80%-39.52% 2.92B
-1.24%-4.95%+120.44%-60.26% 2.66B
Average -1.14%+4.07%+31.36%+22.12% 5.62B
Weighted average by Cap. -1.10%+5.79%+41.83%+65.57%

Financials

2026 *2027 *
Net sales 1.84B 271M 231M 212M 201M 372M 25.97B 376M 2.53B 984M 12.32B 1.02B 997M 42.8B 2.4B 354M 302M 277M 262M 486M 33.89B 490M 3.3B 1.28B 16.07B 1.33B 1.3B 55.85B
Net income 282M 41.52M 35.41M 32.48M 30.74M 56.97M 3.97B 57.52M 387M 151M 1.88B 156M 153M 6.55B 387M 57.03M 48.64M 44.61M 42.23M 78.25M 5.46B 79M 531M 207M 2.59B 214M 209M 9B
Net Debt - -
Logo Sansure Biotech Inc.
Sansure Biotech Inc is a China-based company mainly engaged in providing overall diagnostic solutions. The Company offers an integrated and comprehensive solution covering the entire industrial chain, including reagents, instruments, sequencing services, third-party medical testing services, and the co-construction of molecular laboratories. The Company researches and develops products such as infectious disease prevention and control, maternal and child health, blood safety, cancer prevention and control, and companion diagnostics. The Company operates its business in both domestic and foreign markets.
Employees
2,346
Date Price Change Volume
12/05/26 18.25 ¥ -4.25% 9,835,260
11/05/26 19.06 ¥ +5.19% 16,587,290
08/05/26 18.12 ¥ +3.78% 11,452,020
07/05/26 17.46 ¥ +1.45% 4,691,246
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
18.25CNY
Average target price
22.02CNY
Spread / Average Target
+20.66%

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688289 Stock